Tumor Blueprint Report

The Tumor Blueprint interpretive report that is created by the Clearity Foundation is based on molecular profiling test results. Once our clinical laboratory partners receive the tumor sample, it typically takes 2-3 weeks to receive the results, which are provided to your doctor and to Clearity. The laboratory reports are more detailed and include information about each test and the scientific evidence connecting the test result to drug responses.

Clearity’s summarizes the results from each of the laboratories in one report that is sent to you and your physician approximately two days after the laboratory results are released. This comprehensive report includes all of your test results and compares them to clinical research evidence that associates each test with drug response (see Test Panel for more information). In addition, Clearity interprets your test results in the context of information from the Clearity Database. This comparison enables your individual results to be interpreted relative to those from other ovarian cancer patients.

How do Doctors Use Tumor Blueprints?

The Tumor Blueprint Report shows the results from your tumor molecular profile and the drugs to which your cancer may be sensitive. This information can be used to help prioritize treatment options that would already be considered by your doctor. The molecular profile may also suggest drugs that are available only in a clinical trial and potential clinical trial options will be provided to you. Clearity will review the information in the report with you by telephone to answer any questions you may have.

The Clearity Foundation has provided its molecular profiling service since 2008 and has profiled the tumors of hundreds of women. The Clearity Database records the results from each woman’s Tumor Blueprint, along with information about which therapy was selected and effects of that treatment. Correlating the molecular profiles with treatment outcomes will provide additional evidence for the use of specific biomarkers in guiding treatment decisions. To that end, Clearity has created a separate Data Repository that is de-identified (ie., has no personal identifying information for any patient) but contains clinical and tumor profiling data for use in research studies.